A Single-Dose, Open-Label, Parallel-Group Study to Assess the Pharmacokinetics of Inclisiran in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function (ORION-7)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Inclisiran (Primary)
- Indications Hypercholesterolaemia
- Focus Pharmacokinetics
- Acronyms ORION-7
- Sponsors The Medicines Company
- 10 Oct 2017 Planned End Date changed from 1 Aug 2018 to 1 Sep 2018.
- 10 Oct 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Nov 2017.
- 10 Oct 2017 Status changed from recruiting to active, no longer recruiting.